Cannabis

Iowa House Amendment H-8327 to HF 2748 Clarifies Hemp Product Definitions and Inhalable Hemp Ban

Iowa House amendment H‑8327 to HF 2748, filed on 07 April 2026, would redefine “consumable hemp product” to exclude inhalable hemp products and newly defined “minimally processed hemp”, while classifying compliant hemp and minimally processed hemp as agricultural commodities and farm crops.[^1^](https://www.legis.iowa.gov/legislation/BillBook?ga=91&ba=H8327#:~:text=Sec.%5C_\_\_\_.Section204.2,Minimallyprocessedhempasdefinedinsection204A.2.) If enacted, the change would leave Iowa’s existing criminal ban on inhalable hemp products intact under §204.14A but give hemp growers and processors clearer boundaries between prohibited inhalable products, regulated consumable hemp products, and raw or minimally processed hemp treated as agricultural commodities.[^2^](https://www.legis.iowa.gov/docs/code/2026/204.14A.pdf)

10 Apr 2026, 15:32legis.iowa.govUnited States

Germany BGH Rules Internet Platform Advertising for Medical Cannabis Breaches § 10 HWG

The German Federal Court of Justice (BGH) ruled in March 2026 that internet platforms promoting prescription medical cannabis treatments to the public violate the Therapeutic Products Advertising Act (HWG). This decision reinforces strict limits on digital health marketing, requiring telemedicine and pharmaceutical platforms to overhaul lead-generation and patient-matching workflows to avoid prohibited consumer-facing advertising.

3 Apr 2026, 18:55rechtsprechung-im-internet.deGermany

EU EFSA NDA Panel Cannot Establish Safety of CO2 Hemp Extract Novel Food Under Regulation (EU) 2015/2283

EFSA has issued a negative scientific opinion on CO2 hemp extracts, concluding that safety cannot be established due to insufficient characterization and toxicological data. This decision reinforces the high evidentiary bar for cannabinoid-based novel foods, signaling continued market access delays and the need for more robust, substance-specific safety data.

1 Apr 2026, 18:44efsa.europa.euEuropean Union

Denmark Adopts New Controlled Substances Order (BEK 405 of 2026)

Denmark’s updated Executive Order on euphoriant substances (BEK 405) entered into force on 29 March 2026, replacing the 2021 regulatory framework. Businesses must audit portfolios against updated substance lists and ensure rigorous compliance with tracking, reporting, and security obligations for controlled chemicals and hemp-derived products.

1 Apr 2026, 14:32retsinformation.dkDenmark

EU Notifies Draft Amendment to Regulation (EU) 2023/915 on Δ9‑THC in Hemp Leaf Infusions

The European Commission has proposed maximum levels for Δ9-THC in hemp leaf infusions under Regulation (EU) 2023/915, with a planned application date of January 2027. Manufacturers must prepare for strict concentration limits and mandatory safety labelling to mitigate acute exposure risks, particularly for vulnerable populations.

29 Mar 2026, 19:25docs.wto.orgEuropean Union

Germany (VG Würzburg) Upholds Immediate Enforcement on 'CBD Hemp Oil for Camels' Customer Health Warnings

A German administrative court has upheld immediate enforcement orders requiring health warnings and customer disclosures for CBD products marketed with animal-focused labeling. Businesses should anticipate stricter scrutiny of "playful" branding, as authorities will apply EU food safety standards and traceability requirements regardless of animal-only claims if human consumption is implied.

28 Mar 2026, 20:33gesetze-bayern.deGermanyEuropean Union

EFSA Webinar on Risk Assessment of Cannabidiol as a Novel Food

EFSA will detail its updated safety assessment framework for Cannabidiol (CBD) as a novel food in a webinar on April 21, 2026. This guidance clarifies the scientific evidence required for novel food applications, directly impacting market access and compliance strategies for CBD-based products.

28 Mar 2026, 17:00efsa.europa.euEuropean Union

EU Commission Adopts Delegated Regulation 2026/177 on CAP Hemp THC Controls, Market Withdrawals and GAEC 1

The EU has updated CAP rules to simplify market withdrawal interventions and formalize THC monitoring requirements for hemp cultivation, effective March 2026. Businesses in the hemp and produce sectors should review revised seed certification standards and expenditure caps to ensure continued compliance and optimize subsidy recovery.

27 Mar 2026, 20:54eur-lex.europa.euEuropean Union

Austria Recalls Brownies From Czechia Over High Delta-9-THC and Unauthorised CBD (RASFF 2026.2498)

Austria has issued a serious risk notification and consumer recall for brownies containing excessive Delta-9-THC and unauthorized CBD. This enforcement action underscores the strict EU-wide scrutiny of cannabinoid-infused food products and the ongoing classification of CBD as an unauthorized novel food ingredient.

27 Mar 2026, 11:57webgate.ec.europa.euEuropean UnionAustriaCzechia

Michigan CRA Files Formal Complaints Against Infinite Chemical Analysis Labs (Jackson, Michigan)

Michigan's Cannabis Regulatory Agency has filed formal complaints against a safety compliance laboratory for failing to adhere to approved testing protocols and quality standards. This enforcement action signals heightened oversight of laboratory data integrity and ISO/IEC 17025 compliance, increasing risk for businesses relying on third-party testing for market access.

26 Mar 2026, 12:20michigan.govUnited States

Pennsylvania Proposes Hemp-Derived Cannabinoid Beverage Licensing And Tax Framework (HB 2309)

Pennsylvania introduced HB 2309 in March 2026 to create a comprehensive regulatory, licensing, and taxation framework for hemp-derived cannabinoid beverages. Manufacturers must prepare for strict THC potency limits, mandatory third-party lab testing, and detailed labeling requirements that align hemp-derived products with existing alcohol-style oversight.

25 Mar 2026, 21:37legis.state.pa.usUnited States

Netherlands Customs Updates VGEM Handbook Guidance on Opium Act and Sanctions Controls

Netherlands Customs has updated its VGEM Handbook with detailed enforcement procedures for Opium Act substances and international sanctions compliance. Businesses must ensure precise declaration coding and permit documentation to avoid shipment delays, seizures, or regulatory escalation during risk-based customs inspections.

20 Mar 2026, 13:53kennisbank.douane.nlNetherlands

US DEA Announces Siegfried Grafton Application To Import Schedule I Controlled Substances

The US DEA has announced an application by Siegfried Grafton, Inc. to import Schedule I controlled substances, including GHB and MDMA, for analytical testing and distribution. This highlights the ongoing demand for high-purity controlled substances in R&D and reinforces the strict regulatory oversight governing the supply chain for restricted pharmaceutical precursors.

20 Mar 2026, 13:48federalregister.govUnited States

Minnesota House Introduces HF 4201 on Cannabis and Hemp Licensing and Labelling

Minnesota introduced HF 4201 in March 2026 to tighten cannabis and hemp licensing and mandate stricter labeling and safety symbols for cannabinoid products. Businesses must prepare for operational separation between hemp and cannabis licenses and comprehensive packaging redesigns to meet new warning and testing verification standards.

14 Mar 2026, 07:52revisor.mn.govUnited States

US DEA Seeks Comment on Purisys, LLC Import Registration for Schedule I and II Controlled Substances

The US DEA has published a notice of application for Purisys, LLC to import various Schedule I and II controlled substances, with comments due by April 13, 2026. This move signals potential shifts in the domestic supply chain for pharmaceutical precursors and APIs, offering existing manufacturers a window to contest or support the expanded import capacity.

13 Mar 2026, 13:25federalregister.govUnited States

Minnesota SF 4429 – Proposed Cannabis and Hemp Licensing and Labelling Amendments

Minnesota introduced SF 4429 in March 2026 to overhaul cannabis and hemp licensing, labeling, and THC content standards. Businesses should prepare for stricter labeling mandates, including mandatory safety symbols and testing verification, alongside expanded licensing opportunities across the hemp and cannabis sectors.

13 Mar 2026, 13:16revisor.mn.govUnited States

US HHS (SAMHSA) Confirms Authorized Drug Testing Panels for Federal Workplace Programs

The US Department of Health and Human Services has confirmed that authorized drug testing panels and cut-off concentrations for federal workplace programs remain unchanged for 2026. Employers and certified laboratories should maintain existing testing protocols for urine and oral fluids, as no new analytes or routine biomarker testing have been introduced.

13 Mar 2026, 06:29public-inspection.federalregister.govUnited States

Kentucky House Bill 612 Proposes New Licensing And Taxes For Alcohol, Kratom And Hemp-Derived Cannabinoid Products

Kentucky HB 612 proposes a comprehensive overhaul of the state’s regulatory and tax framework for alcohol, kratom, and hemp-derived cannabinoids, with key changes starting July 2027. This shift requires businesses to recalibrate tax compliance strategies and prepare for heightened enforcement and revised operational licensing standards.

9 Mar 2026, 18:59apps.legislature.ky.govUnited States

Kentucky HB 895 Proposes Department of Psychoactive Substances to Regulate Cannabis, Kratom, and Hemp Products

Kentucky HB 895 proposes centralizing the regulation of cannabis, kratom, and hemp products under a new Department of Psychoactive Substances. This consolidation signals a move toward more rigorous, specialized oversight of product testing, licensing, and market access for psychoactive consumer goods.

9 Mar 2026, 18:58apps.legislature.ky.govUnited States

US DEA Seeks Comment on Maridose LLC Importer Application for Schedule I Cannabis Substances

The US DEA is reviewing an application from Maridose LLC to import Schedule I cannabis substances for research and analysis, with comments due by April 3, 2026. If approved, the move would expand the availability of controlled cannabis extracts and synthetic cannabinoids for clinical testing and pharmaceutical R&D.

9 Mar 2026, 15:26federalregister.govUnited States